Further Data Support Safety, Efficacy of Takeda’s Entyvio for UC, Crohn’s

Further Data Support Safety, Efficacy of Takeda’s Entyvio for UC, Crohn’s
Takeda Pharmaceuticals, which is on the forefront of treating ulcerative colitis and Crohn’s disease with the newly launched Entyvio (vedolizumab), will present data concerning the open-label extension phase 3 study of patients receiving Entyvio for a total of two years. The study, GEMINI LTS (Long-Term Safety), will be discussed in three presentations at the 21st

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *